TY - JOUR JO - Central European Journal of Immunology SN - 1426-3912 VL - 40 IS - 2 PY - 2015 ID - Wang2015 TI - Experimental immunologyBlockade of B-cell activating factor with TACI-IgG effectively reduced Th1 and Th17 cells but not memory T cells in experimental allergic encephalomyelitis mice AB - B-cell activating factor (BAFF) is regarded as a new therapeutic target in autoimmune diseases such as systemic lupus erythematosus (SLE) and multiple sclerosis (MS). Along with other researchers, we have demonstrated that BAFF inhibitor atacicept (TACI-IgG) suppresses lupus and experimental allergic encephalomyelitis (EAE) by reducing the mature B-cell number but not memory B cells. It is however unclear whether TACI-Ig affects pathogenic T cells and memory T cells. In the present study, we found that blocking BAFF with TACI-IgG effectively reduces the pathogenic Th1 and Th17 cells in EAE mice. However, TACI-IgG did not reduce memory CD62L+CD44hiCD4+ and CD62L+CD44hiCD8+ T cells in EAE mice. When interleukin (IL)-15 was neutralized, memory CD62L+CD44hi T cells were significantly reduced in TACI-IgG-treated EAE mice. These results suggest that TACI-IgG is effective in effective controlling Th1 and Th17 cells, but it also increases IL-15 to upregulate memory T cells in EAE mice. The study provides hints for the clinical application of the combination of BAFF- and IL-15-specific therapeutic agents. AU - Wang, Xiaoqian AU - Xiao, He AU - Wei, Yinxiang AU - Liu, Xiaoling AU - Han, Gencheng AU - Chen, Guojiang AU - Hou, Chunmei AU - Shen, Beifen AU - Li, Yan AU - Wang, Renxi SP - 142 EP - 148 DA - 2015 DO - 10.5114/ceji.2015.52826 UR - http://dx.doi.org/10.5114/ceji.2015.52826 ER -